GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced today the completion of key manufacturing, regulatory, clinical, and preclinical milestones for its GEO-MVA vaccine program. These developments position the company to initiate a pivotal Phase 3 immune-bridging study in the fourth quarter of 2026, a critical step toward expanding global capacity for mpox and smallpox vaccines.
The announcement, made on August 6, 2026, highlights that GEO-MVA has successfully achieved GMP (Good Manufacturing Practice) clinical product manufacturing, received regulatory alignment from the European Medicines Agency (EMA), advanced clinical operations, and generated encouraging preclinical immunogenicity data. According to David A. Dodd, Chairman and CEO of GeoVax, “Completion of these milestones marks a significant inflection point for the GEO-MVA program as we prepare to initiate our pivotal immune-bridging study later this year.”
One of the most notable achievements is the completion of a comparative nonclinical immunogenicity study, which evaluated GEO-MVA against the licensed MVA vaccine, Imvanex®. The study demonstrated that GEO-MVA generated robust orthopoxvirus-specific immune responses, as measured by both binding and neutralizing antibody assays. “These findings further strengthen our confidence in GEO-MVA as we prepare to initiate our pivotal immune-bridging study later this year,” Dodd added.
The planned Phase 3 study, which will enroll approximately 500 participants, is designed to compare immune responses generated by GEO-MVA with those of the licensed MVA-BN vaccine using established neutralizing antibody endpoints. Results are expected in mid-2027. The immune-bridging strategy, which aligns with EMA Scientific Advice, offers an expedited regulatory pathway, potentially accelerating the availability of this vaccine to governments and international health organizations.
The importance of this announcement extends beyond GeoVax’s pipeline. The world has witnessed the disruptive impact of mpox outbreaks, and the need for scalable, reliable vaccine supply is critical. GEO-MVA aims to address this by providing an additional source of non-replicating MVA vaccine, which is essential for preparedness programs. GeoVax is actively engaging with government agencies and international preparedness organizations to discuss future procurement and long-term supply requirements.
“With GMP clinical product available and released, an expedited regulatory pathway established, clinical operations progressing, and encouraging preclinical immunogenicity data in hand, we believe completion of these integrated milestones has substantially de-risked GEO-MVA and positions the program to advance into the Phase 3 study,” Dodd stated.
The completion of these milestones also underscores GeoVax’s commitment to capital-efficient development. By leveraging an immune-bridging approach, the company aims to reduce the time and cost typically associated with large-scale efficacy trials, potentially making the vaccine more accessible in a timely manner.
For the biotechnology industry, this development highlights the viability of immune-bridging studies as a regulatory strategy for vaccine approval, especially in public health emergencies. It also exemplifies how smaller companies can play a pivotal role in global health security by developing alternatives to established vaccines.
GeoVax’s progress with GEO-MVA is a testament to its strategic execution. The company has systematically addressed manufacturing, regulatory, clinical, and scientific challenges, setting a solid foundation for the upcoming trial. As the world continues to grapple with infectious disease threats, the successful advancement of GEO-MVA could provide a vital tool in the global defense against mpox and smallpox.
For more information about GeoVax and its programs, visit www.geovax.com.
